Close Menu

NEW YORK (GenomeWeb) – An assay from Asuragen to detect the most common genetic mutation associated with amyotropic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has been shown to have significant advantages over a lab-developed test in an evaluation by researchers at the University of Pennsylvania.

Asuragen's research-use-only PCR test for GC-rich expansion repeats in the gene C9orf72 is part of a growing menu for genotyping extremely hard-to-amplify regions that the firm believes will be valuable to both researchers and pharmaceutical developers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.